Penny Stocks To Keep An Eye On – June 27th

Triller Group, HIVE Digital Technologies, INVO Fertility, Sharplink Gaming, and Recursion Pharmaceuticals are the five Penny stocks to watch today, according to MarketBeat’s stock screener tool. Penny stocks are shares of small companies that trade at very low prices, often under $5 per share. They are typically considered highly speculative investments because they can be very volatile, have low liquidity, and may carry a higher risk of fraud or business failure. These companies had the highest dollar trading volume of any Penny stocks within the last several days.

Triller Group (ILLR)

Triller Group Inc is a us-based company that operates its businesses through Triller Corp which operates as a technology platform and AGBA Group Holding Limited operates as an insurance and wealth distribution platform

HIVE Digital Technologies (HIVE)

HIVE Digital Technologies Ltd. operates as a cryptocurrency mining company in Canada, Sweden, and Iceland. The company engages in the mining and sale of digital currencies, including Ethereum Classic, Bitcoin, and other coins. It also operates data centers; and offers infrastructure solutions. The company was formerly known as HIVE Blockchain Technologies Ltd.

INVO Fertility (IVF)

Sharplink Gaming (SBET)

SharpLink Gaming, Inc. operates as an online technology company that connects sports fans, leagues, and sports websites to sports betting and iGaming content. The company operates through four segments: Affiliate Marketing Services United States, Affiliate Marketing Services International, Sports Gaming Client Services, and SportsHub Games Network.

Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.